IOVANCE BIOTHERAPEUTICS, INC. quarterly report, Q1 FY2017

IOVANCE BIOTHERAPEUTICS, INC. (then Lion Biotechnologies, Inc.) — Q1 2017 Form 10-Q

Reporting period: Three months ended March 31, 2017; filed May 3, 2017. The company was a clinical-stage biotechnology business developing autologous tumor-infiltrating lymphocyte (TIL) therapies for cancer. Its lead program, LN-144, was in a Phase 2 metastatic melanoma trial. The filing reports no commercial products or biopharmaceutical revenue.

Financial performance and position

Amounts below are in U.S. dollars; financial statement figures are converted from thousands to millions where appropriate.

MetricQ1 2017 / March 31, 2017Comparable period / prior year-end
Revenue$0$0 in Q1 2016
Research and development expense$16.6 million$4.2 million in Q1 2016; up 297%
General and administrative expense$4.3 million$2.8 million in Q1 2016; up 51%
Operating loss$20.9 million$7.0 million in Q1 2016
Net loss$20.7 million$6.9 million in Q1 2016
Net loss per share, basic and diluted$0.33$0.14 in Q1 2016
Net cash used in operations$18.8 million$4.6 million in Q1 2016
Cash and cash equivalents$107.1 million$106.7 million at December 31, 2016
Short-term investments$40.1 million$59.8 million at December 31, 2016
Total assets$155.4 million$171.9 million at December 31, 2016
Current liabilities$5.5 million$5.0 million at December 31, 2016
Stockholders’ equity$149.9 million$166.9 million at December 31, 2016

Cash, cash equivalents and short-term investments totaled $147.2 million; reported working capital was $147.1 million. The balance sheet reports no debt. Operating cash use was partly offset by $18.8 million of net investing cash inflow, mainly investment maturities; financing activities provided $0.4 million. Cash increased $0.4 million during the quarter. With no revenue, profit margins are not meaningful.

Material changes and business developments

  • R&D expense rose $12.4 million, primarily from higher manufacturing costs ($5.6 million), payroll and related costs ($2.4 million), clinical trial costs ($1.7 million), consultants and outside services ($2.0 million), and stock-based compensation ($0.8 million).
  • G&A expense increased $1.4 million, reflecting increased stock-based compensation, consulting and legal costs, and payroll.
  • Stock-based compensation totaled $3.3 million, versus $1.8 million in Q1 2016. Weighted-average common shares outstanding increased to 62.3 million from 48.5 million.
  • After quarter-end, the company agreed to fund multi-year clinical and preclinical research with M.D. Anderson, with funding capped at approximately $14.2 million. It also entered into a three-year manufacturing services agreement with PharmaCell to expand TIL manufacturing capacity and support European trial expansion.

Outlook, risks and contingencies

  • Management expected no product sale or licensing revenue in 2017 and anticipated continued losses and increased R&D spending, including for trials, staffing and manufacturing. It believed available funds would cover anticipated operating expenses for at least 12 months from the filing date.
  • The company reported that its ongoing Phase 2 LN-144 study was enrolling patients at ten sites. Development timing and costs remain subject to enrollment, trial duration, safety and efficacy, manufacturing capability and other uncertainties.
  • On April 10, 2017, the company settled an SEC investigation without admitting or denying the findings, agreed to a cease-and-desist order and a $100,000 civil penalty, and agreed to adopt controls for investor-relations and public-relations activities. The filing warns that the order may hinder future capital raising, including by disqualifying the company from certain Regulation D exemptions.
  • Two securities class actions were filed in April 2017 regarding alleged misstatements or omissions connected to former management and an investor-relations firm. The company said it would defend the cases; potential losses could not be estimated at this early stage.
  • A separate New York lawsuit seeks more than $1.5 million, plus interest and attorneys’ fees; the company disputes the claims and asserts counterclaims. The court stayed the case after plaintiffs’ counsel withdrew. The filing also discusses possible claims relating to certain 2016 warrant-share resales; no loss accrual was recorded because the amount could not be estimated.
  • Other commitments include operating lease payments of $2.6 million in total and potential license and collaboration milestone payments. The filing reports no off-balance-sheet arrangements and no material change to previously disclosed risk factors other than the SEC order and securities litigation.

Important facts for investors to verify

  • Trial enrollment, clinical results, safety and efficacy, and the timing and costs of the LN-144 and expanded TIL programs.
  • Cash runway assumptions against the company’s stated plan for rising R&D, clinical, staffing and manufacturing spending.
  • Potential dilution: 7.9 million Series B preferred shares were convertible into common stock, in addition to options, warrants and other awards; these potential shares were excluded from diluted loss per share as anti-dilutive.
  • Developments and potential financial exposure in the SEC-related class actions and the Solomon Capital litigation, including legal costs and any insurance coverage.
  • Funding obligations and deliverables under the M.D. Anderson alliance, as well as the operational impact of the PharmaCell manufacturing agreement.